Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CLASP2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CLASP2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CLASP2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CLASP2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CLASP2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CLASP2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303424 | Skin | AK | regulation of response to wounding | 35/1910 | 167/18723 | 2.73e-05 | 4.77e-04 | 35 |
GO:005125827 | Skin | AK | protein polymerization | 53/1910 | 297/18723 | 3.74e-05 | 6.20e-04 | 53 |
GO:003223126 | Skin | AK | regulation of actin filament bundle assembly | 25/1910 | 105/18723 | 4.19e-05 | 6.70e-04 | 25 |
GO:00070519 | Skin | AK | spindle organization | 37/1910 | 184/18723 | 4.21e-05 | 6.70e-04 | 37 |
GO:006104118 | Skin | AK | regulation of wound healing | 29/1910 | 134/18723 | 7.03e-05 | 1.02e-03 | 29 |
GO:00443198 | Skin | AK | wound healing, spreading of cells | 12/1910 | 34/18723 | 7.88e-05 | 1.09e-03 | 12 |
GO:00905058 | Skin | AK | epiboly involved in wound healing | 12/1910 | 34/18723 | 7.88e-05 | 1.09e-03 | 12 |
GO:005149226 | Skin | AK | regulation of stress fiber assembly | 22/1910 | 91/18723 | 9.30e-05 | 1.25e-03 | 22 |
GO:00905048 | Skin | AK | epiboly | 12/1910 | 35/18723 | 1.09e-04 | 1.41e-03 | 12 |
GO:011002026 | Skin | AK | regulation of actomyosin structure organization | 23/1910 | 100/18723 | 1.47e-04 | 1.76e-03 | 23 |
GO:003103220 | Skin | AK | actomyosin structure organization | 37/1910 | 196/18723 | 1.67e-04 | 1.94e-03 | 37 |
GO:00705079 | Skin | AK | regulation of microtubule cytoskeleton organization | 30/1910 | 148/18723 | 1.85e-04 | 2.12e-03 | 30 |
GO:00512717 | Skin | AK | negative regulation of cellular component movement | 59/1910 | 367/18723 | 2.85e-04 | 2.99e-03 | 59 |
GO:00400137 | Skin | AK | negative regulation of locomotion | 62/1910 | 391/18723 | 2.96e-04 | 3.08e-03 | 62 |
GO:003003826 | Skin | AK | contractile actin filament bundle assembly | 23/1910 | 106/18723 | 3.64e-04 | 3.59e-03 | 23 |
GO:004314926 | Skin | AK | stress fiber assembly | 23/1910 | 106/18723 | 3.64e-04 | 3.59e-03 | 23 |
GO:00020116 | Skin | AK | morphogenesis of an epithelial sheet | 15/1910 | 57/18723 | 4.46e-04 | 4.17e-03 | 15 |
GO:20001467 | Skin | AK | negative regulation of cell motility | 57/1910 | 359/18723 | 4.91e-04 | 4.55e-03 | 57 |
GO:00604857 | Skin | AK | mesenchyme development | 48/1910 | 291/18723 | 5.64e-04 | 5.06e-03 | 48 |
GO:00903078 | Skin | AK | mitotic spindle assembly | 16/1910 | 65/18723 | 6.54e-04 | 5.64e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLASP2 | SNV | Missense_Mutation | | c.1111N>A | p.Asp371Asn | p.D371N | | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
CLASP2 | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | | protein_coding | tolerated(0.23) | benign(0.234) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | | c.1355T>C | p.Val452Ala | p.V452A | | protein_coding | tolerated(0.06) | probably_damaging(0.954) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | rs554149266 | c.1343N>A | p.Arg448Gln | p.R448Q | | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.3842G>T | p.Gly1281Val | p.G1281V | | protein_coding | deleterious(0.03) | possibly_damaging(0.531) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CLASP2 | SNV | Missense_Mutation | novel | c.179N>A | p.Gly60Glu | p.G60E | | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2793N>A | p.Met931Ile | p.M931I | | protein_coding | deleterious(0.01) | benign(0.233) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CLASP2 | SNV | Missense_Mutation | | c.2897C>G | p.Ser966Cys | p.S966C | | protein_coding | deleterious(0.03) | possibly_damaging(0.54) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CLASP2 | SNV | Missense_Mutation | novel | c.2311N>G | p.Leu771Val | p.L771V | | protein_coding | tolerated(0.17) | possibly_damaging(0.875) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CLASP2 | insertion | Nonsense_Mutation | novel | c.2873_2874insCTAGGGATGAGGCCTACATGACCATGGTG | p.Met958IlefsTer2 | p.M958Ifs*2 | | protein_coding | | | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |